Tissue Transglutaminase (tTG, expressed in Baculovirus/Sf9)

Cat. No.	Available in
15200	0.1 mg
15201	1 mg

Specification Sheet

MSDS

Celiac disease is an enteropathy that is characterized by intestinal lesions of variable severity. Tissue-type transglutaminase (tTG) is believed to be the predominant autoantigen for celiac disease, and the corresponding autoantibodies show higher sensitivity and specificity than anti-gliadin antibodies. Highly pure recombinant human tTG is now available to replace the traditionally used tTG fraction from guinea pig.

Tissue-type transglutaminase antigens from DIARECT have been specifically modified for improved handling: exchange of an active site amino acid eliminates the protein cross-linking activity of the enzyme, while maintaining the native three-dimensional structure and the enzyme's secondary GTPase activity. This engineering assures reproducible properties of the antigen preparations by eliminating variable and ill-defined covalent aggregates of tTG antigen and host-cell proteins.

Two recombinant human tissue transglutaminase products are available from DIARECT, expressed in baculovirus / Sf9 insect cells and E.coli, respectively (follow this link for the page of the E.coli-expressed tTG antigen).